Pharmacokinetics of oxytetracycline administered intravenously to 4 to 5-day-old foals.

The research explored the pharmacokinetics of an antibiotic called oxytetracycline when administered intravenously in very young foals; this medication is often employed in the treatment of limb deformities in these animals. The study looked at the risk of slow elimination potentially leading to kidney damage and other adverse effects due to the immature renal systems of the foals.

Introduction and Background

• The study began by discussing the use of oxytetracycline, an antibiotic, which is given to neonatal foals for the treatment of flexural limb deformities.
• The basis for this treatment is unclear, and though there is evidence supporting its use, the large dose that is typically administered, much higher than the antibacterial dose, could bear potential risk.
• The function of renal clearance in the elimination of oxytetracycline from the body was mentioned, with a question raised on how effective this process may be in neonatal animals due to the potential immaturity of their kidneys.
• The research referred to previous studies showing conflicting results on renal functions in young foals, and maybe these discrepancies could be due to the method of drug administration in previous works.

Potential Risks

• There’s a potential risk of kidney damage as oxytetracycline administered intravenously at high doses may be nephrotoxic. A case of oxytetracycline-induced acute renal failure in a neonatal foal was cited as an example.
• Apart from kidney injury, the drug could also pose detrimental effects to cardiovascular function as it is known to chelate calcium ions.
• The potential negative impacts of tetracyclines, the drug class oxytetracycline belongs to, on young animal’s bone and tooth development were also cited. However, the specific effect of oxytetracycline on foals’ bone and teeth hasn’t been reported.

The Research Objective

• The study hypothesized that the pharmacokinetics of oxytetracycline in foals may be different from adult horses, due to either the foals’ immature kidneys, or because of dose-dependent elimination.
• The research aimed to investigate the pharmacokinetics of oxytetracycline administered intravenously to healthy foals, with a dosage of 50 to 67 mg/kg being administered. A formulation without propylene glycol was used to avoid potential cardiovascular effects.

Significance

• The real-world implication of this study lies in preventing potential health risks when treating young foals for limb deformities. The research could help veterinary medicine specialists understand the side effects and clearance rate of oxytetracycline in 4 to 5-day-old foals, and hence make proper dosing decisions to ensure the safe and effective treatment of these young animals.